BRAF and melanoma: Immunotherapy with nivolumab or pembrolizumab should be offered to patients with resected stage IIB/C BRAF wild-type vulvar melanomas, while either of these agents, or a combination of dabrafenib and trametinib may be considered for BRAF-mutant cases.